Please ensure Javascript is enabled for purposes of website accessibility

Pfizer CEO Expects Pivotal Coronavirus Vaccine Data in October

By Cory Renauer - Updated Sep 3, 2020 at 2:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An interim look at trial results from a vaccine that could bring the COVID-19 pandemic to a close is coming soon.

Albert Bourla, the CEO of Pfizer (PFE 0.61%), raised a lot of eyebrows on Thursday morning during a press briefing with biopharmaceutical industry executives leading efforts to develop vaccines and treatments to help mitigate the COVID-19 pandemic.

Speaking off the cuff, Bourla said the company expects interim results from an ongoing pivotal trial by the end of October. He was also careful to bookend his statement with some important caveats concerning the coronavirus vaccine Pfizer's developing in partnership with BioNTech (BNTX -7.54%).

A man with fingers crossed

Image source: Getty Images.

That vaccine candidate, BNT162b2, uses a strand of messenger RNA (mRNA) to coax human cells into producing proteins that resemble SARS-CoV-2 so our immune systems can immediately recognize the real thing as a threat, if necessary. As of Aug. 20, more than 11,000 participants had enrolled in a pivotal trial expected to ultimately involve 30,000 people in more than 100 study locations spread throughout the U.S.

The BNT162 program began with four closely related vaccine candidates, all of which began the first portion of an enormous pivotal in late July. Results from an earlier phase 1 trial reported in August led the partners to select BNT162b2 as the lead candidate.

The partners were encouraged by blood samples that contained antibodies that should prevent SARS-CoV-2 from entering host cells. Seven days after the second dose of BNT162b2 patients were exhibited concentrations of SARS-CoV-2-neutralizing antibodies at concentrations 3.8 times higher than average concentrations of COVID-19 patients that fought off the infection.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$49.57 (0.61%) $0.30
BioNTech SE Stock Quote
BioNTech SE
$169.30 (-7.54%) $-13.81

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.